Evidence map›Paper›PMID 33372148›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Evolution toward beta common chain receptor usage links the matrix proteins of HIV-1 and its ancestors to human erythropoietin.

Francesca Caccuri, Pasqualina D'Ursi, Matteo Uggeri, Antonella Bugatti, Pietro Mazzuca, Alberto Zani, Federica Filippini, Mario Salmona, Domenico Ribatti, Mark Slevin and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Francesca CaccuriDepartment of Molecular and Translational Medicine, University of Brescia Medical School, 25123 Brescia, Italy.ORCID 0000-0002-1923-9033
Pasqualina D'UrsiInstitute of Technologies in Biomedicine, National Research Council, 20090 Segrate, Italy.ORCID 0000-0003-1554-429X
Matteo UggeriInstitute of Technologies in Biomedicine, National Research Council, 20090 Segrate, Italy.
Antonella BugattiDepartment of Molecular and Translational Medicine, University of Brescia Medical School, 25123 Brescia, Italy.
Pietro MazzucaDepartment of Molecular and Translational Medicine, University of Brescia Medical School, 25123 Brescia, Italy.
Alberto ZaniDepartment of Molecular and Translational Medicine, University of Brescia Medical School, 25123 Brescia, Italy.
Federica FilippiniDepartment of Molecular and Translational Medicine, University of Brescia Medical School, 25123 Brescia, Italy.
Mario SalmonaIstituti di Ricovero e Cura a Carattere Assistenziale Istituto di Ricerche Farmacologiche Mario Negri, 20156 Milan, Italy.ORCID 0000-0002-9098-9873
Domenico RibattiDepartment of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, 70124 Bari, Italy.ORCID 0000-0003-4768-8431
Mark SlevinSchool of Healthcare Science, Manchester Metropolitan University, M15GD Manchester, United Kingdom.
Alessandro OrroInstitute of Technologies in Biomedicine, National Research Council, 20090 Segrate, Italy.ORCID 0000-0002-2581-9579
Wuyuan LuInstitute of Human Virology, University of Maryland, Baltimore, MD 21201.
Pietro LiòDepartment of Computer Science and Technology, University of Cambridge, CB3 0FD Cambridge, United Kingdom.
Robert C GalloInstitute of Human Virology, University of Maryland, Baltimore, MD 21201; rgallo@ihv.umaryland.edu arnaldo.caruso@unibs.it.ORCID 0000-0002-3797-7910
Arnaldo CarusoDepartment of Molecular and Translational Medicine, University of Brescia Medical School, 25123 Brescia, Italy; rgallo@ihv.umaryland.edu arnaldo.caruso@unibs.it.
University of Brescia · ITInstitute of Biomedical Technologies · ITUniversity of Maryland, Baltimore · USManchester Metropolitan University · GBMario Negri Institute for Pharmacological Research · ITUniversity of Bari Aldo Moro · ITUniversity of Cambridge · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The HIV-1 matrix protein p17 (p17) is a pleiotropic molecule impacting on different cell types. Its interaction with many cellular proteins underlines the importance of the viral protein as a major determinant of human specific adaptation. We previously showed the proangiogenic capability of p17. Here, by integrating functional analysis and receptor binding, we identify a functional epitope that displays molecular mimicry with human erythropoietin (EPO) and promotes angiogenesis through common beta chain receptor (βCR) activation. The functional EPO-like epitope was found to be present in the matrix protein of HIV-1 ancestors SIV originated in chimpanzees (SIVcpz) and gorillas (SIVgor) but not in that of HIV-2 and its ancestor SIVsmm from sooty mangabeys. According to biological data, evolution of the EPO-like epitope showed a clear differentiation between HIV-1/SIVcpz-gor and HIV-2/SIVsmm branches, thus highlighting this epitope on p17 as a divergent signature discriminating HIV-1 and HIV-2 ancestors. P17 is known to enhance HIV-1 replication. Similarly to other βCR ligands, p17 is capable of attracting and activating HIV-1 target cells and promoting a proinflammatory microenvironment. Thus, it is tempting to speculate that acquisition of an epitope on the matrix proteins of HIV-1 ancestors capable of triggering βCR may have represented a critical step to enhance viral aggressiveness and early human-to-human SIVcpz/gor dissemination. The hypothesis that the p17/βCR interaction and βCR abnormal stimulation may also play a role in sustaining chronic activation and inflammation, thus marking the difference between HIV-1 and HIV-2 in term of pathogenicity, needs further investigation.

Indexed as

Cells, CulturedEpitopesErythropoietinEvolution, Moleculargag Gene Products, Human Immunodeficiency VirusHIV-1HIV-2HIV AntigensHIV SeropositivityHumansMolecular MimicrySimian Immunodeficiency VirusEpitopesEPO protein, humanErythropoietingag Gene Products, Human Immunodeficiency VirusHIV Antigensp17 protein, Human Immunodeficiency Virus Type 1common beta chain receptorHIV-1 and HIV-2 ancestorsHIV-1 evolutionary trajectoryHIV-1 matrix protein p17human erythropoietin

Identifiers

PMID33372148
PMCPMC7812818
OpenAlexW3118100132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.